Sporamin suppresses growth of human esophageal squamous cell carcinoma cells by inhibition of NF‑κB via an AKT‑independent pathway

Qian,Cui‑Juan; Qi,Yong‑Xiao; Chen,Xiao‑Ying; Zeng,Ju‑Ping; Yao,Jun

doi:10.3892/mmr.2017.7772

Sporamin suppresses growth of human esophageal squamous cell carcinoma cells by inhibition of NF‑κB via an AKT‑independent pathway

Authors:
- Cui‑Juan Qian
- Yong‑Xiao Qi
- Xiao‑Ying Chen
- Ju‑Ping Zeng
- Jun Yao
View Affiliations

Affiliations: Institute of Tumor, School of Medicine, Taizhou University, Taizhou, Zhejiang 318000, P.R. China
Published online on: October 12, 2017 https://doi.org/10.3892/mmr.2017.7772
Pages: 9620-9626

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine whether sporamin, a trypsin inhibitor, suppresses the growth of human esophageal squamous cell carcinoma (ESCC) cells in vitro. Sporamin treatment led to the suppression of viability and proliferation of human ESCC cell lines, EC9706 and EC109, as determined by MTT and [3H] thymidine incorporation assays, respectively. Flow cytometry and fluorescence microscopy demonstrated that sporamin significantly induced apoptosis in EC9706 and EC109 cells. Western blotting demonstrated that sporamin downregulated the expression of Bcl‑2 and Bcl‑2 like 1, and upregulated the expression of Bcl‑2‑associated X in EC9706 and EC109 cells. In addition, marked inhibition of nuclear factor (NF)‑κB activation was observed in sporamin‑treated EC9706 and EC109 cells by an electrophoretic mobility shift assay. Sporamin treatment also resulted in reduced expression levels of phosphorylated (p)‑NF‑κB inhibitor α and nuclear NF‑κB p65. However, the expression levels of p‑protein inase (AKT) and its downstream target, p‑p70 S6 kinase, were not markedly altered following sporamin treatment. In conclusion, sporamin may suppress the growth of human ESCC cells via NF‑κB‑dependent and AKT‑independent mechanisms and may act as a promising natural therapeutic agent for the treatment of human ESCC.

View Figures

View References

1	Thrift AP: The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 41:88–95. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y and Muto M: Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 149:1700–1715. 2015. View Article : Google Scholar : PubMed/NCBI
3	Napier KJ, Scheerer M and Misra S: Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
4	Cowie A, Noble F and Underwood T: Strategies to improve outcomes in esophageal adenocarcinoma. Expert Rev Anticancer Ther. 14:677–687. 2014. View Article : Google Scholar : PubMed/NCBI
5	Li PG, Mu TH and Deng L: Anticancer effects of sweet potato protein on human colorectal cancer cells. World J Gastroenterol. 19:3300–3308. 2013. View Article : Google Scholar : PubMed/NCBI
6	Yao J and Qian C: Sporamin induce apoptosis in human tongue carcinoma cells by down-regulating Akt/GSK-3 signaling. Fundam Clin Pharmacol. 25:229–236. 2011. View Article : Google Scholar : PubMed/NCBI
7	Abdel-Latif MM, Kelleher D and Reynolds JV: Potential role of NF-kappaB in esophageal adenocarcinoma: As an emerging molecular target. J Surg Res. 153:172–180. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ng HY, Ko JM, Yu VZ, Ip JC, Dai W, Cal S and Lung ML: DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma. Int J Cancer. 138:2940–2951. 2016. View Article : Google Scholar : PubMed/NCBI
9	Choi YJ, Moon KM, Chung KW, Jeong JW, Park D, Kim DH, Yu BP and Chung HY: The underlying mechanism of proinflammatory NF-κB activation by the mTORC2/Akt/IKKα pathway during skin aging. Oncotarget. 7:52685–52694. 2016. View Article : Google Scholar : PubMed/NCBI
10	Kim C, Cho SK, Kim KD, Nam D, Chung WS, Jang HJ, Lee SG, Shim BS, Sethi G and Ahn KS: β-Caryophyllene oxide potentiates TNFα-induced apoptosis and inhibits invasion through down-modulation of NF-κB-regulated gene products. Apoptosis. 19:708–718. 2014. View Article : Google Scholar : PubMed/NCBI
11	Olechowska-Jarząb A, Ptak-Belowska A and Brzozowski T: Terapeutic importance of apoptosis pathways in pancreatic cancer. Folia Med Cracov. 56:61–70. 2016.
12	Fullard N, Wilson CL and Oakley F: Roles of c-Rel signalling in inflammation and disease. Int J Biochem Cell Biol. 44:851–860. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kanarek N and Ben-Neriah Y: Regulation of NF-κB by ubiquitination and degradation of the IκBs. Immunol Rev. 246:77–94. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ghosh S and Dass JF: Study of pathway cross-talk interactions with NF-κB leading to its activation via ubiquitination or phosphorylation: A brief review. Gene. 584:97–109. 2016. View Article : Google Scholar : PubMed/NCBI
15	Zhang G, Li Z, Wan X, Zhang Y, Zhu R, Liu Z, Ji D, Zhang H, Wu F, Tian H, et al: Repression of Human Hepatocellular Carcinoma Growth by Regulating Met/EGFR/VEGFR-Akt/NF-κB Pathways with Theanine and Its Derivative, (R)-2-(6,8-Dibromo-2-oxo-2H-chromene-3-carboxamido)-5-(ethylamino)-5-oxopentanoic Ethyl Ester (DTBrC). J Agric Food Chem. 64:7002–7013. 2016. View Article : Google Scholar : PubMed/NCBI
16	Cooper JB and Cohen EE: Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck. 31:1086–1094. 2009. View Article : Google Scholar : PubMed/NCBI
17	Yuge K, Kikuchi E, Hagiwara M, Yasumizu Y, Tanaka N, Kosaka T, Miyajima A and Oya M: Nicotine Induces tumor growth and chemoresistance through activation of the PI3K/Akt/mTOR pathway in bladder cancer. Mol Cancer Ther. 14:2112–2120. 2015. View Article : Google Scholar : PubMed/NCBI
18	Bussink J, van der Kogel AJ and Kaanders JH: Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 9:288–296. 2008. View Article : Google Scholar : PubMed/NCBI